



Trendlines January 2021 Update

Misgav, Israel – 1 February 2021 – The Trendlines Group Ltd. (“**Trendlines**” or “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to provide this update about its recent activities and developments.

News from Our Portfolio Companies

[OrthoSpin Ltd.](#), received regulatory clearance from the United States Food and Drug Administration (FDA) for its second generation, robotic, digitally enabled external fixation system for orthopedic treatments.

[ProArc Medical Ltd.](#) (“**ProArc**”) is now funding on [ExitValley Ltd.](#) to bring its ClearRing System for treatment of Benign Prostatic Hyperplasia (“BPH”, and also known as enlarged prostate) to the market. ProArc offers minimally invasive BPH treatment, avoiding the risks of more invasive surgeries while maintaining sexual function.

[Read more about the portfolio companies.](#)

Upcoming Events

CEO of Trendlines Agrifood Fund, Nitza Kardish PhD., and four portfolio companies, namely [Hargol™ FoodTech Ltd.](#), [ViAqua Therapeutics Ltd.](#), [AquiNovo Ltd.](#), and [Biofishency Ltd.](#), will present at the [Israel Singapore Agri-Food Exchange](#) happening on 3-4 February 2021.

Financial Year Ended 2020 Results

Trendlines will release the Group’s unaudited financial results announcement for the financial year ended 31 December 2020 (“**FY2020**”) post trading on the SGXNet on Tuesday, 23 February 2021. Questions regarding the FY2020 financial results can be sent to [Shira Zimmerman](#). The questions and answers will be posted to Trendlines’ investors website thereafter.

MORE TRENDLINES NEWS & UPDATES

If you would like to receive information and news about our organization, companies, and events, [subscribe to the Trendletter](#), our monthly newsletter. [Read the latest Trendletter](#).

To receive links to SGXNet posted announcements, including investor presentations and financial and corporate information, [sign up for investor alerts here](#).

- End -

This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.